牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals PLC, a company with principal executive offices in Cardiff, United Kingdom, has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on February 14, 2024. The amendment, known as Schedule 13G/A, indicates that several reporting persons, including Ionic Ventures LLC, Ionic Management LLC, Brendan O'Neil, and Keith Coulston, have collectively ceased to be the beneficial owners of more than five percent of the company's outstanding American Depositary Shares (ADSs). The filing, which serves as an exit filing for the reporting persons, updates their beneficial ownership information and amends previous disclosures. The ADSs in question represent 400 ordinary shares each, with a nominal value of £0.001 per share. The reporting persons had shared voting...Show More
Biodexa Pharmaceuticals PLC, a company with principal executive offices in Cardiff, United Kingdom, has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on February 14, 2024. The amendment, known as Schedule 13G/A, indicates that several reporting persons, including Ionic Ventures LLC, Ionic Management LLC, Brendan O'Neil, and Keith Coulston, have collectively ceased to be the beneficial owners of more than five percent of the company's outstanding American Depositary Shares (ADSs). The filing, which serves as an exit filing for the reporting persons, updates their beneficial ownership information and amends previous disclosures. The ADSs in question represent 400 ordinary shares each, with a nominal value of £0.001 per share. The reporting persons had shared voting and dispositive power over 135,532 ADSs, which equates to a 4.9% ownership of the class. The amendment also details the limitations on the exercise of certain Series D, E, and F purchase warrants due to beneficial ownership blockers set at 9.99% and 4.99%. The reporting persons' principal business address is in San Francisco, California, and they have entered into a Joint Filing Agreement to file this and any subsequent amendments jointly.
Biodexa Pharmaceuticals PLC是一家主要行政辦公室位於英國加的夫的公司，已成爲2024年2月14日向美國證券交易委員會（SEC）提交的修訂文件的主體。該修正案被稱爲附表13G/A，表明包括Ionic Ventures LLC、Ionic Management LLC、Brendan O'Neil和Keith Coulston在內的幾位申報人集體不再是該公司超過5％的已發行美國存托股份（ADS）的受益所有人。該文件是申報人的退出申報文件，更新了他們的受益所有權信息，並對先前的披露進行了修改。有問題的ADS代表每股400股普通股，名義價值爲每股0.001英鎊。申報人對135...展開全部
Biodexa Pharmaceuticals PLC是一家主要行政辦公室位於英國加的夫的公司，已成爲2024年2月14日向美國證券交易委員會（SEC）提交的修訂文件的主體。該修正案被稱爲附表13G/A，表明包括Ionic Ventures LLC、Ionic Management LLC、Brendan O'Neil和Keith Coulston在內的幾位申報人集體不再是該公司超過5％的已發行美國存托股份（ADS）的受益所有人。該文件是申報人的退出申報文件，更新了他們的受益所有權信息，並對先前的披露進行了修改。有問題的ADS代表每股400股普通股，名義價值爲每股0.001英鎊。申報人對135,532份ADS擁有共同的投票權和處置權，相當於該階層擁有4.9％的所有權。該修正案還詳細規定了某些D、E和F系列購買權證的行使限制，因爲受益所有權封鎖定爲9.99％和4.99％。申報人的主要營業地址位於加利福尼亞州舊金山，他們已簽訂聯合申報協議，共同提交本修正案和任何後續修正案。
有用
沒用